Yahoo
Toronto - Delayed Quote CAD

Apotex Health Corp. (APTX.TO)

30.54 -1.93 (-5.94%)
At close: October 8 at 4:00:01 PM EDT
Chart Range Bar
Loading chart for APTX.TO
  • Previous Close 32.47
  • Open 32.39
  • Bid 30.50 x --
  • Ask 30.54 x --
  • Day's Range 30.46 - 32.39
  • 52 Week Range 26.05 - 40.18
  • Volume 456,595
  • Avg. Volume 493,614
  • Market Cap (intraday) 6.978B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.14
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield 0.06 (0.18%)
  • Ex-Dividend Date Sep 15, 2026
  • 1y Target Est 41.37

Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a broad portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. It operates through three business lines including conventional generic pharmaceuticals; specialty generic pharmaceuticals; and brands & biosimilars. The company has a a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent, Inc. and changed its name to Apotex Health Corp. in May 2026. Apotex Health Corp. was founded in 1974 and is headquartered in Toronto, Canada. Apotex Health Corp. operates as a subsidiary of SK Artemis Holdings, II, LLC

www.apotex.com

6,000

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 10/8/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

APTX.TO
9.07%
S&P/TSX Composite index (^GSPTSE)
10.29%

1-Year Return

APTX.TO
9.07%
S&P/TSX Composite index (^GSPTSE)
15.22%

3-Year Return

APTX.TO
9.07%
S&P/TSX Composite index (^GSPTSE)
82.61%

5-Year Return

APTX.TO
9.07%
S&P/TSX Composite index (^GSPTSE)
72.14%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 847.98M
Earnings -38.34M
Profit Margin -4.52%

Q1

FY27

0
200M
400M
600M
800M
-4.5%

Analyst Insights

View More

Analyst Price Targets

40.00
41.37 Average
30.54 Current
44.30 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 9/22/2026
  • Market Cap

    7.54B

  • Enterprise Value

    10.31B

  • Trailing P/E

    22.65

  • Forward P/E

    16.10

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.36

  • Price/Book (mrq)

    21.54

  • Enterprise Value/Revenue

    3.22

  • Enterprise Value/EBITDA

    22.54

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.85%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    3.2B

  • Net Income Avi to Common (ttm)

    -27.27M

  • Diluted EPS (ttm)

    -0.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    258.76M

  • Total Debt/Equity (mrq)

    863.10%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: